WAM
RIGL icon

Wolverine Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Wolverine Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3
Closed -$1K – 2510
2014
Q1 		$1K Sell
3
-2
-40% -$71 ﹤0.01% 2264
2013
Q4 		$1K Buy
+5
New +$147 ﹤0.01% 2599

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wolverine Asset Management's RIGL Position: Q3 2019 in Review

Wolverine Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2019, closing a stake of 38,000 shares — an estimated $991K sold.

Wolverine Asset Management first reported a position in RIGL in Q2 2013 and held it in 3 quarters. The position peaked at $991K in Q2 2019. 131 funds tracked by Wall St. Rank hold RIGL as of Q3 2019.

  • Wolverine Asset Management reported no remaining Rigel Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Wolverine Asset Management sold 38,000 Rigel Pharmaceuticals shares in Q3 2019, an estimated $991K.
  • Wolverine Asset Management first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Wolverine Asset Management's Rigel Pharmaceuticals position peaked at $991K in Q2 2019.
  • 131 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2019.

Based on Wolverine Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.